FAQ: Where US Pharma Reshoring Stands in 2026

Pharmaceutical Commerce· July 8, 2026

The pharmaceutical industry is assessing the current state of domestic manufacturing reshoring efforts as of 2026 to address long-standing supply chain vulnerabilities. These initiatives aim to reduce reliance on foreign production for critical active pharmaceutical ingredients and finished dosage forms. For the sector, the trajectory of reshoring impacts capital allocation, regulatory alignment, and the overall resilience of the drug supply market.

Read the full story at Pharmaceutical Commerce

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Pharmaceutical Commerce.

More in Pharmaceutical

FDAAA updated to include social media in medication advertising - The Post-Crescent

FDAAA updated to include social media in medication advertising The Post-Crescent

July 11, 2026

Why Illinois patients need the 340B drug program

An opinion piece from The State Journal-Register highlights the significance of the 340B drug pricing program for patients in Illinois. The 340B program is a federal initiative that requires pharmaceutical manufacturers to provide outpatient drugs to eligible healthcare organizations at reduced prices. This discussion is relevant to the pharmaceutical industry as it underscores the regional advocacy for maintaining drug discount programs that impact manufacturer revenue and patient access.

July 11, 2026

How AI accelerates radiopharmaceutical drug discovery, optimizes personalized dosimetry

The integration of deep learning and generative artificial intelligence is significantly accelerating the discovery and development of radiopharmaceutical therapies for oncology. These technological advances allow for the rapid identification of novel targets and the engineering of stable drug candidates, addressing the traditionally time- and resource-intensive nature of this sector. By optimizing personalized dosimetry and treatment planning, AI-driven models aim to maximize tumor damage while minimizing risks to healthy tissue, representing a major shift toward precision cancer therapy.

July 11, 2026

FDA Staffing Cuts Threaten U.S. Drug Innovation Leadership

The House Energy and Commerce Health Subcommittee is scheduled to meet on July 15 to address concerns regarding the Food and Drug Administration's ability to maintain U.S. biomedical innovation leadership. Recent staffing reductions, including the layoff of 3,500 employees, have raised alarms about the agency's capacity to provide timely guidance and predictable approval timelines for new therapies. This development is critical for the pharmaceutical sector as it directly impacts the regulatory pathway for drug and device applicants and could undermine the nation's global competitive standing.

July 10, 2026